Skip to main content
CRIS
NASDAQ Life Sciences

Curis Board Approves 1-for-20 Reverse Stock Split to Maintain Nasdaq Listing

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.492
Mkt Cap
$20.351M
52W Low
$0.181
52W High
$2.482
52W Position info
173% above low
Off High info
80% below high
Rel. Volume info
4.1× avg
Market data snapshot near publication time

CRIS has more than doubled off its 52-week low of $0.181 on elevated volume (4.1× avg).

Summary

Curis Inc.'s Board of Directors has approved a 1-for-20 reverse stock split, finalizing the ratio to address the company's Nasdaq delisting threat.


Key Events · Corporate Governance and Compliance · CRIS

  • Reverse Stock Split Approved

    The Board of Directors approved a 1-for-20 reverse stock split, effective June 25, 2026, following shareholder authorization.

  • Nasdaq Delisting Compliance

    This action is a direct response to the company's delisting notice from Nasdaq, aiming to meet the minimum bid price requirement.

  • Finalizes Board Discretion

    The Board's decision sets the specific 1-for-20 ratio, which was previously approved by shareholders as a range between 1-for-5 and 1-for-25.


Analysis · CRIS · Life Sciences

This filing confirms the Board's decision to implement a 1-for-20 reverse stock split, a critical step to regain compliance with Nasdaq's minimum bid price requirement. The company has been facing a delisting notice and previously disclosed "going concern" doubts, making this action essential for its continued listing on a major exchange. While reverse splits are often viewed negatively as they do not address underlying business issues, this move is necessary to avoid delisting, which would severely impact liquidity and investor confidence.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRIS was trading at $0.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.4M. The 52-week trading range was $0.18 to $2.48. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRIS - Latest Insights

CRIS
Nov 13, 2026, 4:19 PM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $0.445
Real-time Price: $0.430 info
Change: -$0.015 (-3%) info
Market Cap: $4.062M info
CRIS
Nov 13, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.445
Real-time Price: $0.430 info
Change: -$0.015 (-3%) info
Market Cap: $4.062M info
CRIS
Nov 12, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.57165
Real-time Price: $0.430 info
Change: -$0.14165 (-25%) info
Market Cap: $4.062M info
CRIS
Nov 06, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.8481
Real-time Price: $0.430 info
Change: -$0.4181 (-49%) info
Market Cap: $4.062M info
CRIS
Oct 19, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3816
Real-time Price: $0.430 info
Change: +$0.0484 (+13%) info
Market Cap: $4.062M info